HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entryMichael Roche, Paul R. Gorry, Anne Ellett et al.|Retrovirology|2011Cited by 42